First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.

With the dose increase of BAT4406F, the maximum plasma concentration ( C max ), area under concentration‐time curve from 0 to the last measurable timepoint (AUC 0‐t ) and area under concentration‐time curve from 0 to infinity (AUC 0‐inf ) showed an increasing trend, whereas the mean clearance (CL t ), terminal elimination rate ( λ Z ), and apparent volume of distribution ( V d ) decreased.

also in 63,971 other papers